Genenta Science S.p.A. (GNTA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GNTA
- Company Genenta Science S.p.A.
- Price $1.55
- Changes Percentage 7.64
- Change 0.11
- Day Low $1.5
- Day High $1.61
- Year High $10
- Year Low $0.55
- Market Cap $40,399,047
- Price Avg 50 EMA (D) $0.74
- Price Avg 200 EMA (D) $1.75
- Exchange NASDAQ
- Volume 927,774
- Average Volume 1,368,874
- Open $1.5
- Previous Close $1.44
- EPS -0.38
- PE -5.55
- Earnings Announcement 2026-09-02 12:00:00
- Shares Outstanding $19,146,468
Company brief: GENENTA SCIENCE S.P.A. (GNTA )
- Healthcare
- Biotechnology
- Mr. Pierluigi Paracchi
- https://www.genenta.com
- IT
- N/A
- 12-15-2021
- US36870W1009
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.